Sunflower Health advances major asset restructuring plan

Zhejiang Sunflower Great Health Technology Co., Ltd. (Sunflower Health) announced the continued progress of its major asset restructuring. The company plans to acquire 100% equity in Zhangzhou Xipu Material Technology Co., Ltd. and 40% equity in Zhejiang Beide Pharmaceutical Co., Ltd. through a combination of share issuance and cash payments, alongside raising supporting funds. This transaction is categorized as a related party transaction and a major asset restructuring, though it will not result in a backdoor listing.

Sunflower Health shares were suspended from trading on September 8, 2025, and resumed on September 22, 2025. This followed the disclosure of the "Preliminary Plan for Issuing Shares and Paying Cash to Purchase Assets and Raising Supporting Funds for Related Transactions" on September 22, 2025. Audit, valuation, and due diligence efforts related to the transaction are currently underway.

Following the completion of these works, Sunflower Health will convene further board and shareholder meetings to deliberate on the transaction and fulfill information disclosure obligations. The transaction remains subject to approval, ratification, or consent from relevant regulatory authorities.